Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other long lasting clotting factors and more promising drugs are on their way to get launched in this market. For instance, follow up data from phase I/II study of hemophilia medicine ‘Emicizumab’ by Roche has demonstrated promising results regarding safety and prophylactic efficiency in people with severe hemophilia A. Another example is of ‘Eloctate’ for type A and ‘Aprolix’ for type B hemophilia, respectively. These two newly arrived biogen products are opposed to commonly prescribe course of three infusions per week as they are longer-acting than traditional treatments and require only one to two infusions per week, due to their new mechanism of action.
With increasing attention on prophylactic treatment, the market for hemophilia drugs is estimated to have a positive outlook over the coming years. The prophylactic treatment approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline. According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several of such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for prophylactic treatment due to its advantages will drive this market’s growth over the forecast period.The Americas led the global hemophilia drugs market in 2017 and is expected to continue its dominance until the end of 2023. The Americas have the highest revenue share in the global market with the US contributing to the majority of this revenue. Several countries in the region have introduced health care reforms which are having a positive impact on the market growth. Moreover, healthcare reforms in the US have also helped reduce the cost of pharmaceutical drugs, increased access to healthcare, and improved the overall quality of healthcare. These healthcare reforms are likely to have a positive impact on healthcare insurance and also reduce hospital stay and overall medical expenses, which will boost this market’s growth in the region.
This report offers an overview of the market trends, drivers, and barriers with respect to the China Hemophilia Drugs market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Hemophilia Drugs market. Detailed analysis of key players, along with key growth strategies adopted by Hemophilia Drugs industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
Pfizer
F Hoffmann-La Roche
Catalyst Biosciences
Spark Therapeutics
Grifols
Octapharma
Baxalta
CSL Behring
Dimension Therapeutics
Sangamo Biosciences
Bayer
Alnylam Pharmaceuticals
BioMarin
Swedish Orphan Biovitrum
By Type:
Hemophilia A
Inhibitors
Hemophilia B
Von Willebrand Disease
By End-User:
Recombinant Therapies
Plasma-Derived Therapies
By Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of Hemophilia Drugs Market
-
1.3 Market Segment by Type
-
1.3.1 China Hemophilia Drugs Market Size and Growth Rate of Hemophilia A from 2016 to 2027
-
1.3.2 China Hemophilia Drugs Market Size and Growth Rate of Inhibitors from 2016 to 2027
-
1.3.3 China Hemophilia Drugs Market Size and Growth Rate of Hemophilia B from 2016 to 2027
-
1.3.4 China Hemophilia Drugs Market Size and Growth Rate of Von Willebrand Disease from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 China Hemophilia Drugs Market Size and Growth Rate of Recombinant Therapies from 2016 to 2027
-
1.4.2 China Hemophilia Drugs Market Size and Growth Rate of Plasma-Derived Therapies from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 North China Hemophilia Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 Central China Hemophilia Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 South China Hemophilia Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 East China Hemophilia Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.5 Northeast China Hemophilia Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.6 Southwest China Hemophilia Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.7 Northwest China Hemophilia Drugs Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of Hemophilia Drugs Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Commercial Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of Hemophilia Drugs by Major Types
-
3.4.1 Market Size and Growth Rate of Hemophilia A
-
3.4.2 Market Size and Growth Rate of Inhibitors
-
3.4.3 Market Size and Growth Rate of Hemophilia B
-
3.4.4 Market Size and Growth Rate of Von Willebrand Disease
4 Segmentation of Hemophilia Drugs Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of Hemophilia Drugs by Major End-Users
-
4.4.1 Market Size and Growth Rate of Hemophilia Drugs in Recombinant Therapies
-
4.4.2 Market Size and Growth Rate of Hemophilia Drugs in Plasma-Derived Therapies
5 Market Analysis by Regions
-
5.1 China Hemophilia Drugs Production Analysis by Regions
-
5.2 China Hemophilia Drugs Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on China Economy
6 North China Hemophilia Drugs Landscape Analysis
-
6.1 North China Hemophilia Drugs Landscape Analysis by Major Types
-
6.2 North China Hemophilia Drugs Landscape Analysis by Major End-Users
7 Central China Hemophilia Drugs Landscape Analysis
-
7.1 Central China Hemophilia Drugs Landscape Analysis by Major Types
-
7.2 Central China Hemophilia Drugs Landscape Analysis by Major End-Users
8 South China Hemophilia Drugs Landscape Analysis
-
8.1 South China Hemophilia Drugs Landscape Analysis by Major Types
-
8.2 South China Hemophilia Drugs Landscape Analysis by Major End-Users
9 East China Hemophilia Drugs Landscape Analysis
-
9.1 East China Hemophilia Drugs Landscape Analysis by Major Types
-
9.2 East China Hemophilia Drugs Landscape Analysis by Major End-Users
10 Northeast China Hemophilia Drugs Landscape Analysis
-
10.1 Northeast China Hemophilia Drugs Landscape Analysis by Major Types
-
10.2 Northeast China Hemophilia Drugs Landscape Analysis by Major End-Users
11 Southwest China Hemophilia Drugs Landscape Analysis
-
11.1 Southwest China Hemophilia Drugs Landscape Analysis by Major Types
-
11.2 Southwest China Hemophilia Drugs Landscape Analysis by Major End-Users
12 Northwest China Hemophilia Drugs Landscape Analysis
-
12.1 Northwest China Hemophilia Drugs Landscape Analysis by Major Types
-
12.2 Northwest China Hemophilia Drugs Landscape Analysis by Major End-Users
13 Major Players Profiles
-
13.1 Pfizer
-
13.1.1 Pfizer Company Profile and Recent Development
-
13.1.2 Market Performance
-
13.1.3 Product and Service Introduction
-
13.2 F Hoffmann-La Roche
-
13.2.1 F Hoffmann-La Roche Company Profile and Recent Development
-
13.2.2 Market Performance
-
13.2.3 Product and Service Introduction
-
13.3 Catalyst Biosciences
-
13.3.1 Catalyst Biosciences Company Profile and Recent Development
-
13.3.2 Market Performance
-
13.3.3 Product and Service Introduction
-
13.4 Spark Therapeutics
-
13.4.1 Spark Therapeutics Company Profile and Recent Development
-
13.4.2 Market Performance
-
13.4.3 Product and Service Introduction
-
13.5 Grifols
-
13.5.1 Grifols Company Profile and Recent Development
-
13.5.2 Market Performance
-
13.5.3 Product and Service Introduction
-
13.6 Octapharma
-
13.6.1 Octapharma Company Profile and Recent Development
-
13.6.2 Market Performance
-
13.6.3 Product and Service Introduction
-
13.7 Baxalta
-
13.7.1 Baxalta Company Profile and Recent Development
-
13.7.2 Market Performance
-
13.7.3 Product and Service Introduction
-
13.8 CSL Behring
-
13.8.1 CSL Behring Company Profile and Recent Development
-
13.8.2 Market Performance
-
13.8.3 Product and Service Introduction
-
13.9 Dimension Therapeutics
-
13.9.1 Dimension Therapeutics Company Profile and Recent Development
-
13.9.2 Market Performance
-
13.9.3 Product and Service Introduction
-
13.10 Sangamo Biosciences
-
13.10.1 Sangamo Biosciences Company Profile and Recent Development
-
13.10.2 Market Performance
-
13.10.3 Product and Service Introduction
-
13.11 Bayer
-
13.11.1 Bayer Company Profile and Recent Development
-
13.11.2 Market Performance
-
13.11.3 Product and Service Introduction
-
13.12 Alnylam Pharmaceuticals
-
13.12.1 Alnylam Pharmaceuticals Company Profile and Recent Development
-
13.12.2 Market Performance
-
13.12.3 Product and Service Introduction
-
13.13 BioMarin
-
13.13.1 BioMarin Company Profile and Recent Development
-
13.13.2 Market Performance
-
13.13.3 Product and Service Introduction
-
13.14 Swedish Orphan Biovitrum
-
13.14.1 Swedish Orphan Biovitrum Company Profile and Recent Development
-
13.14.2 Market Performance
-
13.14.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure China Hemophilia Drugs Market Size and Growth Rate of Hemophilia A from 2016 to 2027
-
Figure China Hemophilia Drugs Market Size and Growth Rate of Inhibitors from 2016 to 2027
-
Figure China Hemophilia Drugs Market Size and Growth Rate of Hemophilia B from 2016 to 2027
-
Figure China Hemophilia Drugs Market Size and Growth Rate of Von Willebrand Disease from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2021
-
Figure Market Share by Type in 2027
-
Figure China Hemophilia Drugs Market Size and Growth Rate of Recombinant Therapies from 2016 to 2027
-
Figure China Hemophilia Drugs Market Size and Growth Rate of Plasma-Derived Therapies from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2021
-
Figure Market Share by End-User in 2027
-
Figure North China Hemophilia Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Central China Hemophilia Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South China Hemophilia Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure East China Hemophilia Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast China Hemophilia Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Southwest China Hemophilia Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northwest China Hemophilia Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of Hemophilia Drugs Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2020
-
Figure Market Share of TOP 5 Players in 2021
-
Figure Market Share of TOP 6 Players from 2016 to 2021
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Map of China
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of Hemophilia Drugs
-
Figure Development Trends of Different Types
-
Table Commercial Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of Hemophilia Drugs by Different Types from 2016 to 2027
-
Table Consumption Share of Hemophilia Drugs by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of Hemophilia A
-
Figure Market Size and Growth Rate of Inhibitors
-
Figure Market Size and Growth Rate of Hemophilia B
-
Figure Market Size and Growth Rate of Von Willebrand Disease
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of Hemophilia Drugs by Different End-Users from 2016 to 2027
-
Table Consumption Share of Hemophilia Drugs by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Recombinant Therapies
-
Figure Market Size and Growth Rate of Plasma-Derived Therapies
-
Table China Hemophilia Drugs Production by Regions
-
Table China Hemophilia Drugs Production Share by Regions
-
Figure China Hemophilia Drugs Production Share by Regions in 2016
-
Figure China Hemophilia Drugs Production Share by Regions in 2021
-
Figure China Hemophilia Drugs Production Share by Regions in 2027
-
Table China Hemophilia Drugs Consumption by Regions
-
Table China Hemophilia Drugs Consumption Share by Regions
-
Figure China Hemophilia Drugs Consumption Share by Regions in 2016
-
Figure China Hemophilia Drugs Consumption Share by Regions in 2021
-
Figure China Hemophilia Drugs Consumption Share by Regions in 2027
-
Table North China Hemophilia Drugs Consumption by Types from 2016 to 2027
-
Table North China Hemophilia Drugs Consumption Share by Types from 2016 to 2027
-
Figure North China Hemophilia Drugs Consumption Share by Types in 2016
-
Figure North China Hemophilia Drugs Consumption Share by Types in 2021
-
Figure North China Hemophilia Drugs Consumption Share by Types in 2027
-
Table North China Hemophilia Drugs Consumption by End-Users from 2016 to 2027
-
Table North China Hemophilia Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure North China Hemophilia Drugs Consumption Share by End-Users in 2016
-
Figure North China Hemophilia Drugs Consumption Share by End-Users in 2021
-
Figure North China Hemophilia Drugs Consumption Share by End-Users in 2027
-
Table Central China Hemophilia Drugs Consumption by Types from 2016 to 2027
-
Table Central China Hemophilia Drugs Consumption Share by Types from 2016 to 2027
-
Figure Central China Hemophilia Drugs Consumption Share by Types in 2016
-
Figure Central China Hemophilia Drugs Consumption Share by Types in 2021
-
Figure Central China Hemophilia Drugs Consumption Share by Types in 2027
-
Table Central China Hemophilia Drugs Consumption by End-Users from 2016 to 2027
-
Table Central China Hemophilia Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Central China Hemophilia Drugs Consumption Share by End-Users in 2016
-
Figure Central China Hemophilia Drugs Consumption Share by End-Users in 2021
-
Figure Central China Hemophilia Drugs Consumption Share by End-Users in 2027
-
Table South China Hemophilia Drugs Consumption by Types from 2016 to 2027
-
Table South China Hemophilia Drugs Consumption Share by Types from 2016 to 2027
-
Figure South China Hemophilia Drugs Consumption Share by Types in 2016
-
Figure South China Hemophilia Drugs Consumption Share by Types in 2021
-
Figure South China Hemophilia Drugs Consumption Share by Types in 2027
-
Table South China Hemophilia Drugs Consumption by End-Users from 2016 to 2027
-
Table South China Hemophilia Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure South China Hemophilia Drugs Consumption Share by End-Users in 2016
-
Figure South China Hemophilia Drugs Consumption Share by End-Users in 2021
-
Figure South China Hemophilia Drugs Consumption Share by End-Users in 2027
-
Table East China Hemophilia Drugs Consumption by Types from 2016 to 2027
-
Table East China Hemophilia Drugs Consumption Share by Types from 2016 to 2027
-
Figure East China Hemophilia Drugs Consumption Share by Types in 2016
-
Figure East China Hemophilia Drugs Consumption Share by Types in 2021
-
Figure East China Hemophilia Drugs Consumption Share by Types in 2027
-
Table East China Hemophilia Drugs Consumption by End-Users from 2016 to 2027
-
Table East China Hemophilia Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure East China Hemophilia Drugs Consumption Share by End-Users in 2016
-
Figure East China Hemophilia Drugs Consumption Share by End-Users in 2021
-
Figure East China Hemophilia Drugs Consumption Share by End-Users in 2027
-
Table Northeast China Hemophilia Drugs Consumption by Types from 2016 to 2027
-
Table Northeast China Hemophilia Drugs Consumption Share by Types from 2016 to 2027
-
Figure Northeast China Hemophilia Drugs Consumption Share by Types in 2016
-
Figure Northeast China Hemophilia Drugs Consumption Share by Types in 2021
-
Figure Northeast China Hemophilia Drugs Consumption Share by Types in 2027
-
Table Northeast China Hemophilia Drugs Consumption by End-Users from 2016 to 2027
-
Table Northeast China Hemophilia Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast China Hemophilia Drugs Consumption Share by End-Users in 2016
-
Figure Northeast China Hemophilia Drugs Consumption Share by End-Users in 2021
-
Figure Northeast China Hemophilia Drugs Consumption Share by End-Users in 2027
-
Table Southwest China Hemophilia Drugs Consumption by Types from 2016 to 2027
-
Table Southwest China Hemophilia Drugs Consumption Share by Types from 2016 to 2027
-
Figure Southwest China Hemophilia Drugs Consumption Share by Types in 2016
-
Figure Southwest China Hemophilia Drugs Consumption Share by Types in 2021
-
Figure Southwest China Hemophilia Drugs Consumption Share by Types in 2027
-
Table Southwest China Hemophilia Drugs Consumption by End-Users from 2016 to 2027
-
Table Southwest China Hemophilia Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Southwest China Hemophilia Drugs Consumption Share by End-Users in 2016
-
Figure Southwest China Hemophilia Drugs Consumption Share by End-Users in 2021
-
Figure Southwest China Hemophilia Drugs Consumption Share by End-Users in 2027
-
Table Northwest China Hemophilia Drugs Consumption by Types from 2016 to 2027
-
Table Northwest China Hemophilia Drugs Consumption Share by Types from 2016 to 2027
-
Figure Northwest China Hemophilia Drugs Consumption Share by Types in 2016
-
Figure Northwest China Hemophilia Drugs Consumption Share by Types in 2021
-
Figure Northwest China Hemophilia Drugs Consumption Share by Types in 2027
-
Table Northwest China Hemophilia Drugs Consumption by End-Users from 2016 to 2027
-
Table Northwest China Hemophilia Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Northwest China Hemophilia Drugs Consumption Share by End-Users in 2016
-
Figure Northwest China Hemophilia Drugs Consumption Share by End-Users in 2021
-
Figure Northwest China Hemophilia Drugs Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of Pfizer
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer
-
Figure Sales and Growth Rate Analysis of Pfizer
-
Figure Revenue and Market Share Analysis of Pfizer
-
Table Product and Service Introduction of Pfizer
-
Table Company Profile and Development Status of F Hoffmann-La Roche
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of F Hoffmann-La Roche
-
Figure Sales and Growth Rate Analysis of F Hoffmann-La Roche
-
Figure Revenue and Market Share Analysis of F Hoffmann-La Roche
-
Table Product and Service Introduction of F Hoffmann-La Roche
-
Table Company Profile and Development Status of Catalyst Biosciences
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Catalyst Biosciences
-
Figure Sales and Growth Rate Analysis of Catalyst Biosciences
-
Figure Revenue and Market Share Analysis of Catalyst Biosciences
-
Table Product and Service Introduction of Catalyst Biosciences
-
Table Company Profile and Development Status of Spark Therapeutics
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Spark Therapeutics
-
Figure Sales and Growth Rate Analysis of Spark Therapeutics
-
Figure Revenue and Market Share Analysis of Spark Therapeutics
-
Table Product and Service Introduction of Spark Therapeutics
-
Table Company Profile and Development Status of Grifols
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Grifols
-
Figure Sales and Growth Rate Analysis of Grifols
-
Figure Revenue and Market Share Analysis of Grifols
-
Table Product and Service Introduction of Grifols
-
Table Company Profile and Development Status of Octapharma
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Octapharma
-
Figure Sales and Growth Rate Analysis of Octapharma
-
Figure Revenue and Market Share Analysis of Octapharma
-
Table Product and Service Introduction of Octapharma
-
Table Company Profile and Development Status of Baxalta
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Baxalta
-
Figure Sales and Growth Rate Analysis of Baxalta
-
Figure Revenue and Market Share Analysis of Baxalta
-
Table Product and Service Introduction of Baxalta
-
Table Company Profile and Development Status of CSL Behring
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of CSL Behring
-
Figure Sales and Growth Rate Analysis of CSL Behring
-
Figure Revenue and Market Share Analysis of CSL Behring
-
Table Product and Service Introduction of CSL Behring
-
Table Company Profile and Development Status of Dimension Therapeutics
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Dimension Therapeutics
-
Figure Sales and Growth Rate Analysis of Dimension Therapeutics
-
Figure Revenue and Market Share Analysis of Dimension Therapeutics
-
Table Product and Service Introduction of Dimension Therapeutics
-
Table Company Profile and Development Status of Sangamo Biosciences
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sangamo Biosciences
-
Figure Sales and Growth Rate Analysis of Sangamo Biosciences
-
Figure Revenue and Market Share Analysis of Sangamo Biosciences
-
Table Product and Service Introduction of Sangamo Biosciences
-
Table Company Profile and Development Status of Bayer
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bayer
-
Figure Sales and Growth Rate Analysis of Bayer
-
Figure Revenue and Market Share Analysis of Bayer
-
Table Product and Service Introduction of Bayer
-
Table Company Profile and Development Status of Alnylam Pharmaceuticals
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Alnylam Pharmaceuticals
-
Figure Sales and Growth Rate Analysis of Alnylam Pharmaceuticals
-
Figure Revenue and Market Share Analysis of Alnylam Pharmaceuticals
-
Table Product and Service Introduction of Alnylam Pharmaceuticals
-
Table Company Profile and Development Status of BioMarin
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of BioMarin
-
Figure Sales and Growth Rate Analysis of BioMarin
-
Figure Revenue and Market Share Analysis of BioMarin
-
Table Product and Service Introduction of BioMarin
-
Table Company Profile and Development Status of Swedish Orphan Biovitrum
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Swedish Orphan Biovitrum
-
Figure Sales and Growth Rate Analysis of Swedish Orphan Biovitrum
-
Figure Revenue and Market Share Analysis of Swedish Orphan Biovitrum
-
Table Product and Service Introduction of Swedish Orphan Biovitrum
-
